Horizon Investment Services LLC Invests $208,000 in United Therapeutics Co. (NASDAQ:UTHR)

Horizon Investment Services LLC acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 654 shares of the biotechnology company’s stock, valued at approximately $208,000.

Several other hedge funds have also recently bought and sold shares of the company. Norges Bank purchased a new position in United Therapeutics in the 4th quarter valued at approximately $100,519,000. Swedbank AB acquired a new position in United Therapeutics during the 1st quarter worth $97,316,000. Nordea Investment Management AB increased its holdings in United Therapeutics by 677.6% during the 1st quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after purchasing an additional 262,222 shares during the period. Avidity Partners Management LP acquired a new stake in United Therapeutics in the 4th quarter valued at about $52,158,000. Finally, Canada Pension Plan Investment Board grew its position in shares of United Therapeutics by 567.2% during the first quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after buying an additional 153,700 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of a number of recent analyst reports. Bank of America reduced their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. UBS Group increased their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, July 8th. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $400.00 target price on shares of United Therapeutics in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $350.36.

United Therapeutics Stock Down 1.0 %

Shares of NASDAQ:UTHR opened at $350.01 on Friday. The company has a market cap of $15.53 billion, a price-to-earnings ratio of 16.55, a PEG ratio of 1.31 and a beta of 0.55. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $366.08. The firm’s 50-day simple moving average is $333.29 and its 200-day simple moving average is $281.92. The company has a quick ratio of 4.18, a current ratio of 4.35 and a debt-to-equity ratio of 0.02.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. United Therapeutics’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.24 EPS. As a group, equities research analysts predict that United Therapeutics Co. will post 24.86 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 7,785 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the transaction, the chief financial officer now directly owns 2,615 shares in the company, valued at $947,597.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total value of $93,722.29. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $45,293.30. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO James Edgemond sold 7,785 shares of United Therapeutics stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the transaction, the chief financial officer now owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. The disclosure for this sale can be found here. Over the last quarter, insiders sold 119,520 shares of company stock valued at $38,572,141. 12.50% of the stock is owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.